115,990 Shares in Omnicell, Inc. $OMCL Bought by Trillium Asset Management LLC

Trillium Asset Management LLC bought a new position in shares of Omnicell, Inc. (NASDAQ:OMCL) during the 2nd quarter, Holdings Channel.com reports. The firm bought 115,990 shares of the company’s stock, valued at approximately $4,816,000.

Several other institutional investors also recently bought and sold shares of OMCL. AQR Capital Management LLC boosted its stake in shares of Omnicell by 42.1% during the 1st quarter. AQR Capital Management LLC now owns 17,936 shares of the company’s stock worth $627,000 after acquiring an additional 5,311 shares in the last quarter. Empowered Funds LLC lifted its holdings in Omnicell by 14.3% in the 1st quarter. Empowered Funds LLC now owns 9,953 shares of the company’s stock worth $348,000 after purchasing an additional 1,243 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Omnicell by 4.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 124,047 shares of the company’s stock worth $4,337,000 after purchasing an additional 4,866 shares during the last quarter. Jane Street Group LLC lifted its holdings in Omnicell by 201.5% in the 1st quarter. Jane Street Group LLC now owns 163,664 shares of the company’s stock worth $5,722,000 after purchasing an additional 109,382 shares during the last quarter. Finally, Creative Planning boosted its position in Omnicell by 16.7% during the second quarter. Creative Planning now owns 9,390 shares of the company’s stock worth $276,000 after purchasing an additional 1,347 shares during the period. 97.70% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have commented on OMCL shares. Zacks Research downgraded Omnicell from a “hold” rating to a “strong sell” rating in a report on Friday, August 7th. Piper Sandler reaffirmed an “overweight” rating and set a $45.00 price objective (down from $55.00) on shares of Omnicell in a report on Monday, August 3rd. Weiss Ratings raised shares of Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday. Craig Hallum reiterated a “buy” rating and issued a $55.00 target price on shares of Omnicell in a research note on Wednesday, April 29th. Finally, Wall Street Zen upgraded shares of Omnicell from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 10th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Omnicell presently has a consensus rating of “Moderate Buy” and an average price target of $57.86.

Key Headlines Impacting Omnicell

Here are the key news stories impacting Omnicell this week:

• Positive Sentiment: Zacks raised its FY2026 EPS estimate for Omnicell to $1.49 from $1.27, above the $1.30 consensus estimate. It also modestly increased its FY2028 forecast to $1.73 from $1.71, suggesting some longer-term earnings potential.
• Neutral Sentiment: The FY2026 estimate remains well below Omnicell’s stated full-year 2026 guidance of $2.15-$2.30 EPS, highlighting a significant disagreement between company expectations and the analyst’s forecast. The company’s latest reported quarter was stronger than expected, with $0.94 EPS and $312.2 million in revenue, but investors are focused on forward estimates.
• Negative Sentiment: Zacks reduced its Q3 2026 EPS estimate to $0.25 from $0.27 and sharply cut Q4 2026 EPS to $0.07 from $0.31. It also lowered Q1 2027 EPS to $0.25 from $0.31, Q2 2027 EPS to $0.23 from $0.32, Q3 2027 EPS to $0.32 from $0.33, and FY2027 EPS to $1.27 from $1.34. These cuts imply weaker near-term profitability and are likely the primary reason for the negative market sentiment. Zacks Research Has Negative Outlook for Omnicell Q1 Earnings

Omnicell Price Performance

Shares of NASDAQ:OMCL opened at $35.50 on Friday. The company has a market cap of $1.61 billion, a price-to-earnings ratio of 42.26, a PEG ratio of 0.91 and a beta of 0.98. The business has a 50 day moving average price of $40.42 and a 200 day moving average price of $39.71. The company has a quick ratio of 1.43, a current ratio of 1.64 and a debt-to-equity ratio of 0.13. Omnicell, Inc. has a twelve month low of $29.06 and a twelve month high of $55.00.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.94 EPS for the quarter, topping the consensus estimate of $0.47 by $0.47. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.The company had revenue of $312.21 million for the quarter, compared to the consensus estimate of $310.21 million. During the same period in the previous year, the business posted $0.45 EPS. The company’s revenue for the quarter was up 7.4% on a year-over-year basis. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Research analysts predict that Omnicell, Inc. will post 1.41 earnings per share for the current year.

Omnicell Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.